NK CellTech recently announced the completion of a Series A financing round of over 100 million CNY, led by HUAGAI Capital and followed by CAS FOF, Unifortune Group, Chase Capital, Sirius Capital and Qiaojing Capital. The funds raised in this round will be used to accelerate the development and registration of multiple NK cell product pipelines.
Science and Technology Department of the City of Shanghai recently announced the list of the 4th batch of National Science and Technology-based Small and Medium-sized Enterprises in 2022 in which NK CellTech, as an invisible unicorn company in the field of tumor immunotherapy, was listed in the database.
Telephone:021-50888199
Email: contact@nk-celltech.com
Our location:Building 7, Lane 100, Banxia Road, Zhoupu Town, Pudong New Area, Shanghai
© Copyright by CSPC All rights reserved. ICP备字：沪ICP备2022013361号-1
